Relay Therapeutics (RLAY) Stock Price, News & Analysis

-0.01 (-0.17%)
(As of 04/22/2024 ET)
Today's Range
50-Day Range
52-Week Range
1.06 million shs
Average Volume
1.15 million shs
Market Capitalization
$780.52 million
P/E Ratio
Dividend Yield
Price Target

Relay Therapeutics MarketRank™ Stock Analysis

Analyst Rating
3.00 Rating Score
337.0% Upside
$26.00 Price Target
Short Interest
8.52% of Shares Sold Short
Dividend Strength
News Sentiment
-0.51mentions of Relay Therapeutics in the last 14 days
Based on 3 Articles This Week
Insider Trading
Selling Shares
$43,814 Sold Last Quarter
Proj. Earnings Growth
From ($2.84) to ($2.69) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.88 out of 5 stars

Medical Sector

587th out of 909 stocks

Biological Products, Except Diagnostic Industry

99th out of 154 stocks

RLAY stock logo

About Relay Therapeutics Stock (NASDAQ:RLAY)

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors. In addition, it has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of GDC-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

RLAY Stock Price History

RLAY Stock News Headlines

[Shocking] Elon Musk’s Plan To End Banks
Leaked Elon Musk call reveals shocking plan to replace banks. As Musk's plan rolls out, industry experts predict it could spark a wave of mass crypto adoption. Triggering a new crypto bull run. While helping drive a booming crypto asset class up from $2.5-billion to $16-trillion (a 6,400x increase) by 2030.
RLAY Apr 2024 7.500 call
RLAY Apr 2024 7.500 put
[Shocking] Elon Musk’s Plan To End Banks
Leaked Elon Musk call reveals shocking plan to replace banks. As Musk's plan rolls out, industry experts predict it could spark a wave of mass crypto adoption. Triggering a new crypto bull run. While helping drive a booming crypto asset class up from $2.5-billion to $16-trillion (a 6,400x increase) by 2030.
Relay Therapeutics (NASDAQ: RLAY)
Relay Therapeutics's Earnings: A Preview
Relay Therapeutics Inc (RLAY)
RLAY Mar 2024 7.500 put
VERV Mar 2024 12.500 call
See More Headlines
Receive RLAY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Relay Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Biological products, except diagnostic
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
5 Analysts


Net Income
Net Margins
Pretax Margin


Sales & Book Value

Annual Sales
$25.55 million
Book Value
$5.90 per share


Free Float
Market Cap
$780.52 million
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

RLAY Stock Analysis - Frequently Asked Questions

Should I buy or sell Relay Therapeutics stock right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Relay Therapeutics in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" RLAY shares.
View RLAY analyst ratings
or view top-rated stocks.

What is Relay Therapeutics' stock price target for 2024?

5 analysts have issued 1-year price objectives for Relay Therapeutics' stock. Their RLAY share price targets range from $17.00 to $33.00. On average, they anticipate the company's share price to reach $26.00 in the next twelve months. This suggests a possible upside of 337.0% from the stock's current price.
View analysts price targets for RLAY
or view top-rated stocks among Wall Street analysts.

How have RLAY shares performed in 2024?

Relay Therapeutics' stock was trading at $11.01 at the beginning of the year. Since then, RLAY stock has decreased by 46.0% and is now trading at $5.95.
View the best growth stocks for 2024 here

When is Relay Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our RLAY earnings forecast

How were Relay Therapeutics' earnings last quarter?

Relay Therapeutics, Inc. (NASDAQ:RLAY) posted its quarterly earnings data on Thursday, February, 22nd. The company reported ($0.67) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.76) by $0.09. Relay Therapeutics had a negative trailing twelve-month return on equity of 42.43% and a negative net margin of 1,263.49%. During the same period in the previous year, the business posted ($0.56) earnings per share.

What ETFs hold Relay Therapeutics' stock?

ETFs with the largest weight of Relay Therapeutics (NASDAQ:RLAY) stock in their portfolio include TrueShares Technology, AI & Deep Learning ETF (LRNZ).Tema Oncology ETF (CANC).

What other stocks do shareholders of Relay Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Relay Therapeutics investors own include Beyond Meat (BYND), CureVac (CVAC), QuidelOrtho (QDEL), Teladoc Health (TDOC), Tesla (TSLA), Datadog (DDOG), DraftKings (DKNG), eHealth (EHTH), GoHealth (GOCO) and Intel (INTC).

When did Relay Therapeutics IPO?

Relay Therapeutics (RLAY) raised $250 million in an initial public offering (IPO) on Thursday, July 16th 2020. The company issued 14,700,000 shares at $16.00-$18.00 per share. J.P. Morgan, Goldman Sachs, Cowen and Guggenheim Securities served as the underwriters for the IPO.

Who are Relay Therapeutics' major shareholders?

Relay Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include Congress Asset Management Co. MA (0.11%), TrueMark Investments LLC (0.04%), Mesirow Financial Investment Management Inc. (0.01%), Los Angeles Capital Management LLC (0.01%) and Allspring Global Investments Holdings LLC (0.01%). Insiders that own company stock include Andy Porter, Brian Adams, Donald A Bergstrom, Mark Murcko, Peter Rahmer, Sanjiv Patel and Thomas Catinazzo.
View institutional ownership trends

How do I buy shares of Relay Therapeutics?

Shares of RLAY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:RLAY) was last updated on 4/22/2024 by Staff

From Our Partners